Items where authors include "Lawson, M.A."
Article
Harrop, R. orcid.org/0009-0006-2743-6842, Blount, D.G. orcid.org/0009-0008-7145-0478, Khan, N. orcid.org/0000-0002-1433-8454 et al. (11 more authors) (2025) Targeting the tumour antigen 5T4 using CAR-T cells for the treatment of Acute Myeloid Leukaemia. Molecular Cancer Therapeutics, 24 (1). pp. 93-104. ISSN 1535-7163
Hodgson, K., Orozco-Moreno, M. orcid.org/0000-0002-6180-7882, Goode, E.A. et al. (29 more authors) (2024) Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. eBioMedicine, 104. 105163. ISSN 2352-3964
Diaz-delCastillo, M. orcid.org/0000-0001-7719-6839, Palasca, O., Nemler, T.T. et al. (18 more authors) (2023) Metastatic infiltration of nervous tissue and periosteal nerve sprouting in multiple myeloma-induced bone pain in mice and human. The Journal of Neuroscience, 43 (29). pp. 5414-5430. ISSN 0270-6474
Tazzyman, S., Stewart, G.R., Yeomans, J. orcid.org/0000-0002-9546-3600 et al. (6 more authors) (2023) HSV1716 prevents myeloma cell regrowth when combined with bortezomib in vitro and significantly reduces systemic tumor growth in mouse models. Viruses, 15 (3). 603. ISSN 1999-4915
Tippett, V.L. orcid.org/0000-0003-1601-3546, Tattersall, L. orcid.org/0000-0001-8835-0627, Ab Latif, N.B. orcid.org/0000-0003-1499-9049 et al. (3 more authors) (2023) The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review. Oncogene, 42 (4). pp. 259-277. ISSN 0950-9232
Tattersall, L. orcid.org/0000-0001-8835-0627, Shah, K.M. orcid.org/0000-0001-9909-6409, Lath, D.L. et al. (11 more authors) (2021) The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties. Journal of Bone Oncology, 31. 100398.
Andrews, R.E., Brown, J.E. orcid.org/0000-0003-4960-3032, Lawson, M.A. orcid.org/0000-0002-5446-923X et al. (1 more author) (2021) Myeloma bone disease : the osteoblast in the spotlight. Journal of Clinical Medicine, 10 (17). 3973.
Ottewell, P.D. orcid.org/0000-0002-4826-0771 and Lawson, M.A. orcid.org/0000-0002-5446-923X (2021) Advances in murine models of breast cancer bone disease. Journal of Cancer Metastasis and Treatment, 7. 11. ISSN 2394-4722
Crawford, L.J., Campbell, D.C., Morgan, J.J. et al. (10 more authors) (2020) The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene, 39 (27). pp. 5001-5014. ISSN 0950-9232
Marino, S., Carrasco, G., Li, B. et al. (5 more authors) (2020) JZL184, a monoacylglycerol lipase inhibitor, induces bone loss in a multiple myeloma model of immunocompetent mice. Calcified Tissue International, 107 (1). pp. 72-85. ISSN 0171-967X
Diaz-delCastillo, M., Kamstrup, D., Olsen, R.B. et al. (6 more authors) (2020) Differential pain-related behaviors and bone disease in immunocompetent mouse models of myeloma. JBMR Plus, 4 (2). e10252. ISSN 2473-4039
Green, A.C. orcid.org/0000-0002-0175-1485, Lath, D. orcid.org/0000-0001-5454-9419, Hudson, K. et al. (8 more authors) (2019) TGFβ inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model. Journal of Bone and Mineral Research, 34 (12). pp. 2311-2326. ISSN 0884-0431
Legge, C.J., Colley, H.E. orcid.org/0000-0003-0053-7468, Lawson, M.A. et al. (1 more author) (2019) Targeted magnetic nanoparticle hyperthermia for the treatment of oral cancer. Journal of Oral Pathology & Medicine, 48 (9). pp. 803-809. ISSN 0904-2512
Paton-Hough, J., Tazzyman, S., Evans, H. et al. (6 more authors) (2019) Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research, 34 (5). pp. 783-796. ISSN 0884-0431
Faraahi, Z., Baud'huin, M., Croucher, P.I. et al. (2 more authors) (2019) Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells. Bone, 122. pp. 82-92. ISSN 8756-3282
Lath, D.L. orcid.org/0000-0001-5454-9419, Buckle, C.H., Evans, H.R. et al. (4 more authors) (2018) ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS One, 13 (6). e0199517. ISSN 1932-6203
Ring, E.S., Lawson, M.A., Snowden, J.A. et al. (2 more authors) (2018) New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International, 102 (2). pp. 196-209. ISSN 0171-967X
Chinnaiya, K., Lawson, M.A. orcid.org/0000-0002-5446-923X, Thomas, S. orcid.org/0000-0002-0027-0815 et al. (8 more authors) (2017) Low-dose methotrexate in myeloproliferative neoplasm models. Haematologica, 102 (6). 165738. ISSN 0390-6078
Lawson, M.A. orcid.org/0000-0002-5446-923X, Ebetino, F.H., Mazur, A. et al. (14 more authors) (2017) The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). Journal of Bone and Mineral Research, 32 (9). pp. 1860-1869. ISSN 0884-0431
Lawson, M.A., McDonald, M.M., Kovacic, N. et al. (18 more authors) (2015) Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 6. 8983.
Lawson, M.A., Paton-Hough, J.M., Evans, H.R. et al. (5 more authors) (2015) NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLOS ONE, 10 (3). e0119546. ISSN 1932-6203
Buckle, C.H., De Leenheer, E., Lawson, M.A. et al. (5 more authors) (2012) Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma. PLoS ONE, 7 (8). e41127. ISSN 1932-6203
Vitovski, S., Chantry, A.D., Lawson, M.A. et al. (1 more author) (2012) Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo. PLoS ONE, 7 (5). e35830. ISSN 1932-6203
Proceedings Paper
Mueller, L.M.E., Parrish, C., Migneco, G. et al. (6 more authors) (2017) Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy. In: Clinical Cancer Research. Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies, 06-09 May 2017, Boston, MA. American Association for Cancer Research , p. 18.